Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Many calves develop pneumonia days before showing symptoms. Lung ultrasounds are helping veterinarians detect the hidden ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Investing.com -- Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares fell 10% in after-hours trading Thursday following the company’s announcement of a proposed public offering of common stock.

HER2-targeted ADCs show ~50% response rates in pretreated endometrial cancer, with durable responses and manageable safety ...

Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...

Trevi Therapeutics, Inc. TRVI shares are trading higher after the company announced the pricing of its $150 million offering ...

CytomX Therapeutics’ latest earnings call struck an upbeat tone as management highlighted robust efficacy signals, improving safety, and a clearer path toward registration for Varseta‑M in metastatic ...

The company's shares recently gained nearly 10% in a week, closing at 87.00 EUR, as it presented compelling evidence for its strategic shift into oncology. The most striking data came from a Phase 2 ...

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...

Patients with SSc who have gastric dysmotility present with a more severe disease phenotype and are associated with an increased risk for adverse outcomes.